Results 21 to 30 of about 1,330 (154)

Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study [PDF]

Journal of the American College of Emergency Physicians Open
Objectives This study describes clinical characteristics and management strategies for patients with factor Xa (FXa) inhibitor–related traumatic non‐intracranial bleeds who were treated with andexanet alfa or four‐factor prothrombin complex concentrate ...
Paul P. Dobesh, Craig I. Coleman, Mark Danese, Eva Lesén, Raymond C. Chang, Onivefu Odelade, Gregory J. Fermann   +6 more
doaj   +2 more sources

Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report [PDF]

Heliyon
Recently, anticoagulant reversal has become a treatment option for life-threatening bleeding, especially in intracranial hemorrhage. Although evidence of the beneficial efficacy of andexanet alfa accumulates in cases of intracranial hemorrhage, little is
Yasunori Shirakawa, Naoto Jingami, Yoshitaka Ishiguro, Takuma Minami, Ken Shinozuka, Tomoyuki Yunoki, Shigeru Ohtsuru   +6 more
doaj   +2 more sources

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring [PDF]

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +2 more sources

Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa [PDF]

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Objective: To evaluate prescribing practices for the anti-Xa reversal agent, andexanet alfa, to identify challenges in ordering and administering this medication, and to offer recommendations to improve patient safety.
Krystof Stanek, MD, Mohammad T. Hussain, MD, Aaron C. Spaulding, PhD, Shalmali Borkar, MD, MPH, Marwan E. Shaikh, MD   +4 more
doaj   +2 more sources

In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra

Research and Practice in Thrombosis and Haemostasis, 2022
Background Both andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) are clinically applied reversal agents for direct factor Xa inhibitors (FXaIs) in emergency situations. Controversy exists whether 4F‐PCC is as effective as andexanet
Herm Jan M. Brinkman, Marleen Zuurveld, Joost C. M. Meijers   +2 more
doaj   +1 more source

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source

Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events

Thrombosis Update, 2021
Background: Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation.
Awatif Hafiz, Alshaya Abdulrahman I, Katelyn W. Sylvester, Jean M. Connors, Jessica Rimsans   +4 more
doaj   +1 more source

Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa

Clinical and Applied Thrombosis/Hemostasis, 2022
Introduction Andexanet alfa (andexanet) is an approved antidote used to reverse the bleeding effects of Direct Oral Anticoagulant (Direct-Xa agents) agents because it reverses anti-Xa activity.
Joseph Lewis BA, Omer Iqbal MD, Walter Jeske PhD, Debra Hoppensteadt PhD, Fakiha Siddiqui BDS, Jawed Fareed PhD   +5 more
doaj   +1 more source

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Critical Care, 2022
Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding.
Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman   +6 more
doaj   +1 more source

Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint [PDF]

Cardiology Journal, 2023
Jacek Kubica, Piotr Adamski, Robert Gajda, Mariusz Gąsior, Marek Gierlotka, Robert Gil, Miłosz Jaguszewski, Aldona Kubica, Wiktor Kuliczkowski, Krzysztof Kurek, Jerzy Robert Ładny, Piotr Michalski, Eliano Pio Navarese, Piotr Niezgoda, Małgorzata Ostrowska, Agnieszka Tycińska   +15 more
doaj   +2 more sources